• Describe how postmortem brain studies validate and refine antemortem biomarkers in Alzheimer’s disease and related dementias (ADRD).

  • Compare clinico-pathologic correlations in mixed-pathology cases (AD/LBD/TDP-43) across amyloid, tau, and α-synuclein biomarkers.

  • Evaluate current limitations and opportunities in biomarkers for ADRD, and how neuropathology can be used to validate biomarker development.

Session date: 
10/27/2025 - 4:00pm to 5:00pm CDT
Location: 
In-person and Virtually
1685 Highland Ave
MFCB-Room 1220
United States
See map: Google Maps
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™
Add to calendar: 
Please login or register to take this course.
Discloser List CME Internal Report